POLE and endometrial cancer: Somatic alterations in the exonuclease domain of POLE occur in a subgroup of endometrial cancers with ultra-mutation (frequently ≥100 mutations/Mb) [9] and excellent clinical outcome [9, 11–13]; the former was replicated in the C-CAT cohort and the latter in the NCCH cohort.